Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSTEP-N in Healthy Adults
NCT07064564Phase 1Active, not recruiting
- Sponsor
- Akyso Therapeutics
- Start
- Jul 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 1, randomised trial of naltrexone in opioid use disorder (OUD) (3 arms), sponsored by Akyso Therapeutics. Primary endpoint: Average plasma naltrexone concentration at Day 336. Started Jul 2026; status: active, not recruiting.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07064564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064564.